Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model

Fig. 1

ACT with a combination of Teff + Tmem resulted in optimal control of melanoma growth. Mice bearing B16GP33 (a) or B16F10 (b) melanoma were untreated (control) or treated with ACT of 105 GP33-specific CD8+ T cells one day after tumor inoculation. Serial tumor measurements confirmed that ACT resulted in a GP33-specific inhibition of melanoma tumor growth. (c) Mice bearing B16GP33 melanoma were treated 7 days after tumor inoculation with no treatment (control) or 105 Teff, 105 Tmem, or 5 × 104 Teff + 5 × 104 Tmem. Comparison of treated groups (d) demonstrates optimal control of melanoma growth with combinatorial ACT. This experiment was repeated three times with similar results, 4–5 mice per group. (+ p < 0.05 compared with control; * p < 0.05 compared with effector ACT; Ɨ p < 0.05 compared with memory ACT)

Back to article page